Oral anticoagulant treatment and risk of kidney disease-a nationwide, population-based cohort study.

ABSTRACT:

Background

Direct oral anticoagulants (DOACs) are recommended as first-line treatment of atrial fibrillation. Whether DOAC use is associated with lower risks of kidney complications compared with vitamin K antagonists (VKAs) remains unclear. We examined this association in a nationwide, population-based cohort study.

Methods

We conducted a cohort study including patients initiating oral anticoagulant treatment within 3 months after an atrial fibrillation diagnosis in Denmark during 2012-18. Using routinely collected creatinine measurements from laboratory databases, we followed patients in an intention-to-treat approach for acute kidney injury (AKI) and chronic kidney disease (CKD) progression. We used propensity-score weighting to balance baseline confounders, computed weig

SUBMITTER: Vestergaard AEF 

PROVIDER: S-EPMC10768770 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature